STING1 and neoplasm: Pharmacologically upregulating the STING pathway alone as an immunotherapy is unlikely to be successful as the recruited tumour specific T-cells can initiate immune inhibitory pathways including PD-L1 or FOXP3, thus preventing tumour clearance [96,97].